Interestingly, monthly treatment with tocilizumab, which has a half‐life of 13 days at the 8 mg kg−1 dose,79 was found to decrease clinical activity of AD in three patients treated for up to 12 months.44 This was the first indication in humans that inhibition of both mIL‐6R and sIL‐6R could be helpful to treat allergic diseases. The gene discussed is IL6R; the disease is allergic disease.